The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1312
May 18, 2009
View Complete Issue         Table of Contents 2019 
Encapsulated Mesalamine Granules (Apriso) for Ulcerative Colitis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Encapsulated Mesalamine Granules (Apriso) for Ulcerative Colitis
May 18, 2009 (Issue: 1312)
Apriso (Salix) is a new formulation of mesalamine (5-aminosalicylic acid; 5-ASA) approved by the FDA for maintenance of remission in mild to moderate ulcerative colitis (UC). Mesalamine is a locally acting antiinflammatory agent that is widely used...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Encapsulated Mesalamine Granules (Apriso) for Ulcerative Colitis
Article code: 1312b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.